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1. Introduction 
1.1 Concept 
1.1.1 Proteomics 
The performer of life functions is the dynamically-changing protein, rather than the relatively-
static gene. Accordingly, the study of protein is of practical significance in the explication of 
vital phenomena, especially in the revelation of onset, deterioration and outcome of human 
diseases, which is also a driving force for the emergence of proteomics. Wilkins and Williams 
(Wasinger VC. et al, 1995) initiated the study of proteomics by putting forward the concept of 
proteomics for the first time. The proteome is the set of expressed proteins in a given type of 
cells, tissues or an organism at a given time under defined conditions. Proteomics is the large-
scale study of proteomes, to discover composition and expression of proteins in organism, to 
understand interactions between proteins and explore functions of proteins and laws of vital 
activities of cells. It covers expression proteomics, functional proteomics and cell-localization 
proteomics etc. The proteomics technologies has provided a new tool for studying the 
biomarkers, pathogeny mechanism, diagnostic methods of diseases. 
1.1.2 Serum proteomics 
When proteomics comes to the clinical applications, it mainly refers to serum proteomics. 
The features of serum proteome research: firstly, it is easily to access samples, which means 
that it is able to meet the research requirements and easy to standardize; secondly, the 
dynamic variation in serum proteins is capable to reflect the pathological changing state of 
human organs; this is of far-reaching importance for disease diagnosis and curative effect 
monitoring. Human Proteome Organization (HUPO) brought the human plasma/serum 
proteome plan under the first-phase of the human proteome plans, which is showing the 
significance of studying serum proteomics for healthy and sick states of human. 
Taking all proteins expressed in the serum of selected target clusters as the object, the serum 
proteomics, based on the normal protein expression profiles, aims to look for the differential 
proteins and define disease-associated proteins, the structures and functions of which will 
further be studied. In the hope of presenting a new approach for studying the pathological 
and physiological mechanisms of severe diseases, specific protein markers are expected to 
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be found for early diagnosis and drug targets. Compared with the tissue proteins and cell 
proteins, serum proteins are unique in many aspects such as the largest number (tens of 
thousands of varieties), extremely great difference in contents of proteins (with a difference 
of more than 108-1012), extremely instable variety and content of low-abundance proteins. 
The main components of serum proteins are albumin and immunoglobulin, which share the 
features like high abundance, large molecular weight and easy-to-detect. Besides, non-
protein substances like lipids and salts also exist in the serum. All other components will 
interfere with the study of small-molecular-weight proteins in the serum. Usually, all the 
important information come from the low-abundance proteins and small-molecular-weight 
proteins with great varieties and different properties, on the other hand, the features of 
these proteins make them difficult to be separated and identified. 
1.1.3 Serum peptidomics 
With the deepening of biological study of proteins, a kind of non-protein intermediate that 
composes of amino acid is discovered and described as polypeptide. According to 
biochemists, peptides are short polymers of amino acids linked by amino bonds (also called 
peptide bonds). Polypeptide is a kind of peptides with more than 10 amino acids (if fewer 
than 10, they are called oligo-peptides). In our study here, proteins with the molecular 
weight less than 10KDa fall into the category of the polypeptides. Besides molecular 
weights, the polypeptides are also different from proteins in functions: firstly, the 
polypeptide are information messenger, which can arouse various physiological activities 
and regulate biochemical response; secondly, polypeptide have high bioactivity; thirdly, as 
smaller molecule, the structure of polypeptide is easier to rebuild and simpler for artificial 
synthesis and chemosynthesis; fourthly, fragments of polypeptide can be used for further 
research of protein features and changing and synthesizing proteins as basic materials. The 
polypeptide is a sort of biologically active substance related to cell functions of organisms. 
Tens of thousands of polypeptides have been found existing in organisms and can be 
synthesized in all cells. Moreover, nearly all cells are regulated by polypeptides, which play 
a role in hormone, nerves, cell growth and reproduction, etc. Presently, in company with the 
instant development of proteomics and mass-spectrometric technology, more and more 
researchers are turning their eyes to polypeptide, which thereby bring about the proteomics-
based peptidomics. 
The main clinical application of peptidomics is the serum peptidomics. The serum 
peptidome, generally referring to serum peptidome profiling, is to detect the accurate mass 
value of polypeptide in serum by mass spectrometry and process mass spectrum with the 
bioinformatics method to build a polypeptide profiling. In the profiling, the peptidome 
identified by an accurate mass value can be further analyzed into amino acid sequence 
through tandem mass spectrometer, thereby used to identify the precursor proteins and 
their biogenetic derivation. Through contrasting differences in the serum peptidome 
profiling of the patients and the healthy controls, proteins or polypeptides specifically 
expressed in disease state and the biomarkers associated with diseases can be discovered to 
perform the studies of proteins related to early diagnosis, classification and subtype, onset 
mechanism of diseases. The serum polypeptide profiling is reputed to be a "brand-new 
health fingerprinting library" technology (Tarnaris A et al, 2006) and has become a research 
hotspot of proteomics. 
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1.2 History of serum peptidomics platform 
Such are three major technical approaches for proteomics study as two-dimensional gel 
electrophoresis (2-DE), mass spectrometry (MS) and bioinformatics. Similar to the 
proteomics technology, serum peptidomics technology also involves in technical 
advancement and upgrade in sample preparation, detection and result analysis, which 
jointly constitute a platform in serum peptidomics research. Most of studies rely on matrix-
assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). 
The working principle of MALDI-TOF-MS is: the pulse laser is utilized to force the matrix to 
absorb energy from laser so that the solid-phase polypeptide samples are ionized; the 
ionized peptides are put into the TOF mass analyzer and separated due to difference in the 
mass-to-charge ratio (m/z); the peptide mass fingerprint (PMF), peptide sequence tag (PST) 
or the amino acid sequences can be obtained through measuring peptide ions; qualitative 
identification or quantitative analysis of peptides can be accomplished through searching in 
the proteome database with corresponding software. On this basis, three serum peptidomics 
research platforms have been developed successfully. 
1.2.1 The 1
st
 generation of serum peptidomics platform: SELDI 
Different from MALDI-TOF-MS, the surface enhanced laser desorption/ionization(SELDI) 
time of flight mass spectrometry platform combines the protein chip with multiple high 
technologies (highly integrated, ultra-micro, computerized, automat-zed) based on the 
chromatogram principle, thereby to strengthen the affinity and capture ability of the chip so 
that proteins are selectively absorbed by the chemically-modified solid surface. The proteins 
captured by the chip surface are ionized in the ion source and their weight is detected by 
referring to the different flight time in the flight tube. In this platform, protein chip is the 
core of the whole system. 
Distinguished by chemical modification, the protein chip is divided into hydrophobic 
surface (H4), normal phase (NP), weak cation exchange (WCX), strong anion exchange 
(SAX) and immobilized metal affinity capture (IMAC) which are aim to fit for different 
detecting requirement. Different chemisorption media allows an extremely large amount of 
proteins to be reduced to a relatively low level, those remained proteins can be absorbed by 
the surface of chip. They are characterized by: (1) can be directly used for crude biological 
samples, such as serum, urine, body fluid and cell lysis solution, etc. (2) low dosage of 
sample is required, generally is 0.5-15l or 2000 cells; (3) high throughput with automatic 
operation; (4) rapid discovery for multiple biomarkers and some low-abundance, small-
molecular-weight proteins; (5)high sensitivity lower the limitation of detection (LOD) to 
1fmol (10-15mol); (6) special identification ability for hydrophobic protein, especially for 
membrane proteins; (7) a high-efficiency and cost-effective system integrates all the protein 
separation, purification, identification, detection and data analysis process. 
The processing and analysis system produces the results in forms like scanning profiling, 
bar graph and electrophoresis patterns (simulation gel image) and analyses the difference 
among two or more groups of results to find out the special mass spectra of identification 
information. The procedure includes: (1) database building; (2) internal and external 
information calibration; (3) data processing and analysis.  
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The data processing of serum protein profiles commonly includes peak detection, data 
grouping, marker selection, marker evaluation and composite mode building. In 
information analysis and processing, two algorithms will be used: (1) non-monitoring 
algorithm, like self-organizing cluster analysis; (2) monitoring algorithm, like artificial 
neural network (ANN). These two, especially the latter one, are more and more found in 
studies regarding tumor diagnosis with satisfying results. 
SELDI, however, has some disadvantages: it is incapable of identifying differential proteins 
screened online; in the profiling, the peak height and protein concentration not always have 
a linear relationship; in the detection process, many factors are involved but the control 
method hasn't been standardized yet, which leads to poor reproduction quality of 
characteristic peaks of the same disease among different researchers. 
1.2.2 The 2
nd
 generation of serum peptidomics research technology system: ClinProt 
To overcome the defects of SELDI, the ClinProt platform with functional magnetic beads, 
AnchorChip technology, MALDI-TOF-MS and ClinProTools has been developed. This 
platform has magnetic bead separating system, MS detecting system, analysis software and 
optional body fluid sample automatic processing system. The basic procedure is as follows: 
first of all, samples like serum, plasma, urine and cerebrospinal fluid, etc. from patients or 
the healthy controls have their high-abundance proteins and other impurities like salts to be 
eliminated and have the low-abundance proteins to be enriched with the magnetic bead. 
After separation and purification, samples are mixed with matrixes and directly drip on the 
AnchorChip target plate, and then protein mass spectrogram can be obtained through time-
of-flight-MS (TOF-MS). The analysis software is employed to compare the differential 
expressed proteins of the patients or the healthy controls to get the specific mass spectra of 
the both for predicting the category of unknown samples (sick or healthy). Therefore, the 
core of this platform is the magnetic bead system and the software system. 
Magnetic reagents include magnetic beads based Weak Cation Exchange (MB-WCX), 
Immobilized Metal Ion Affinity Chromatography Cu (MB-IMAC Cu) and Reverse Phase 
C18 (MB-RPC18), etc. The principle of magnetic beads is that the target proteins firstly 
combine with the magnetic microsphere surface ligand reversibility; secondly they will 
move in an outer magnetic field with a set direction by utilizing the magnetism of the 
magnetic beads to rapidly separate from surrounding medium. Compared with 
conventional technologies, the features of magnetic beads are: with large total surface area 
of magnetic beads, the specific basic groups on the surface can sufficiently combine with the 
low-abundance proteins in the serum to enhance the varieties of proteins, thereby to ensure 
the favorable specificity of the system; with simple and rapid operation, preliminary 
treatment can be finished through the simple blending, washing and elution process, which 
is suitable for clinical examination; the magnetic bead system has very high repetitiveness 
due to its large surface area; the liquid automatic processing system is a high throughput 
platform, it is capable to handle as many as 30,000 samples per day. 
ClinProTools is a bioinformatics software boasting of all functions of biomarker detection 
and evaluation and capable of performing pre-processing of data, obtaining powerful, 
intuitive and visualized data from massive sample groups, carrying out peak statistics and 
pattern recognition, cluster analysis and independent test of data sensitivity, cross 
validation of specificity and meeting the classification demand of unknown samples. 
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Compared with SELDI, the magnetic bead particles have a larger total surface area due to 
their shapes and have stronger combining capacity, higher sensitivity and accuracy, so they 
perfectly cater for the research requirement of serum small-molecular proteins. 
Furthermore, biomarkers combined with the magnetic beads can be eluted, so this 
technology is suitable for MS and satisfy the requirement of sequential analysis in the 
further study. ClinProt system is able to perform the sequence identification task for the 
differentially expressed polypeptides/proteins to clearly distinct whether they are known or 
not. 
1.2.3 The 3
rd
 generation of serum peptidomics research platform: ClinTOF 
Considering features of the serum polypeptide profiling and defects of the ClinProt system, 
it is fair to say that ClinTOF is the representative of the latest platform up to now. 
On one hand, ClinTOF is capable of detecting the biomarker pattern or biomarker profiling 
indicating specific diseases in the biological liquid; on the other hand, this technology can 
identify the candidate for a single biomarker. ClinTOF composes of three parts, including 
magnetic beads, time-of-flight mass spectrometer (TOF MS) and analysis software 
BioExploer ™. 
1. Magnetic Beads 
The magnetic beads includes hydrophobic magnetic beads, metal affinity magnetic beads, 
ion exchange magnetic beads, glycoprotein magnetic beads and immunoaffinity magnetic 
beads. Further, SPE-C magnetic beads, the reagent dedicated for the serum polypeptide 
fingerprint diagnosis is available. Presently, magnetic beads have been found in 
biomedicine fields like immuno-magnetic separation (IMS), cell and cell organelle 
separation, microorganism detection and nucleic acid hybridization. The whole system is 
used in the clinical research of serum peptidomics. 
2. TOF MS 
Time-of-flight mass spectrometer (TOF MS) is used to obtain mass ratio and content of 
proteins captured by magnetic beads. ClinTOF, the clinical mass spectrometer, has adopted 
the cutting-edge 60Hz pulsed nitrogen laser which allows the data generated at the fastest 
speed compared with its counterparts. The zoom optics technology is employed with the 
laser speckle ranging from 50µm to 200 µm (adjustable), also the greatest adjustable range 
among like products, so that the size of laser speckles can meet the demands of different 
samples. The unique gap design in ion source has been utilized, keeping ion sources from 
contaminations and greatly reducing maintenance frequency. The laser system has been 
added with the laser energy leveling function, presenting more stable light intensity of the 
laser and more accurate data. The unique touch screen design has integrated MALDI-TOF 
control system and the PC system, making operations more simple and handy.  
3. Analysis Software BioExploer™ 
BioExploer™ software is used both in processing genetic data and also protein data. 
BioExploer™ has combined visualized analysis and multiple mathematical algorithms to 
build pattern recognition models for MS data classification and forecast, and hunt the 
disease markers from data. It can perform data visualization, data reduction and data 
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mining over various types of MS data and build category prediction models. This software 
features: data of multiple forms can be analyzed with this software even if they have 
converted their formats; signal spectrogram can be visualized through the virtual gel graph 
and stack diagram; wavelet transform is used to deal with the mass spectrogram, including 
baseline elimination, spectrogram smoothing, peak selection and normalization; random 
statistical analysis can be made on one and more groups of spectrogram protein peaks; 
compatibility analysis is designed for the pairing data; the building and verification of the 
pattern recognition models involve in optimistic algorithms including genetic algorithm, 
radial basis neural network and the support vector machine and allow users to select the 
modeling space; output of data analysis reports and backup and storage at any moment. 
The BioExploer™ control and analysis system adopts the display forms of scanning 
profiling (Fig.1) and electrophoresis patterns (simulation gel graph) (Fig.2). Statistical 
analysis graphs include the 3D sample distribution diagram (Fig.3), typical value-variogram 
(Fig.4) and 3D stack diagram (Fig.5). The user may switch the three graphs by clicking the 
three buttons at the lower left corner. 
 
Fig. 1. ClinTOF System Scanning Profiling 
 
Fig. 2. Electrophoresis Graph of the ClinTOF System 
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Fig. 3. ClinTOF System 3D Sample Distribution Diagram 
 
Fig. 4. ClinTOF System Typical Value Variogram 
 
Fig. 5. ClinTOF System 3D Stack Diagram 
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4. Applications of ClinTOF Platform 
ClinTOF can be used in disease peptidomics, early tumor diagnosis and curative effect 
evaluation, mental disease diagnosis, biomarker discovery, microorganism identification, 
single nucleotide polymorphism (SNP) detection and medicine quality control. This system 
as a breakthrough can detect more than 200 polypeptides at the same time by utilizing 
magnetic bead reagent, mass spectrometry and pattern analysis. BIOYONG is the only 
manufacturer in China for ClinTOF system development and certification and has obtained 
many patents. For the moment, this technology has been widely used in the clinical based 
researches, granted a solid scientific foundation for future promotion. 
Besides the intrinsically strength of MALDI-TOF, the ClinTOF system has improved its 
stability and repeatability for clinical analysis. So far, it has detected more than 10,000 
clinical samples and established detection models for colon and rectal cancers, lung cancer, 
hepatic carcinoma and brain glioma. Its accuracy for the early detection of cancers is above 
85% and its specificity and sensitivity exceed 80%. MS models for some tumors based on the 
Clin TOF system have been built and many patents have gained authorization.  
The ClinTOF system has been widely applied in studies on the early diagnosis of ovarian 
cancer, prostatic cancer, breast cancer, brain glioma, head and neck squamous cell 
carcinomas (HNSCC) and carcinoma of urinary bladder and disease diagnosis models have 
been built. For the colon and rectal cancers, the model is shown in Table 1. In the model 
built in the experiment, 70 of the normal cases and 60 of colon and rectal cancer cases are 
used; 31 of the normal cases and 35 of colon and rectal cancer cases are used; the sensitivity 
of the model is 84.17% and the specificity, 95.95%. For the model verified by blind samples, 
the normal/colon and rectal cancer cases is (31/35) and the sensitivity and specificity of the 
model both exceed 80%, with the accuracy reaching 84.85%. For the hepatic carcinoma, the 
diagnosis model is shown in Table 2. According to the established standard operating  
   
Fig. 6. Hepato Carcinoma Diagnosis Model of the ClinTOF System 
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procedure (SOP), BIOYONG has studied the polypeptide  profiling of the 200 hepatic 
carcinoma cases and 200 normal serum cases. 28 differential polypeptides (P<0.0001) were 
obtained, with the molecular weight of 900 ~5000Da (Fig.6). Among them, 9 were down 
regulated (2.5~8 times) and 19 up-regulated (2.5~20 times). For the model built with SNN, the 
recognition rate is 100% and predictive ability, 98.39%. 100 samples were used for double-
blind determination, with the correctness rate exceeding 90%.  
  Training Set  Testing Set  
Sensitivity  84.17% 77.4%(24/31) 
Specificity  95.95% 91.4%(32/35) 
Positive Predictive Value (PPV) --- 88.89%(24/27) 
Negative Predictive Value (NPV) --- 82.1%(32/39) 
Accuracy  --- 84.85(56/66) 
Table 1. Colon and Rectal Cancer Diagnosis Model of the ClinTOF System  
Performance  Bruker Bioyong CipherGen CipherGen 
microflex ClinTOF PBSII/C PCS4000 
Laser light 
source 
nitrogen 337nm 1-
20Hz adjustable
nitrogen 337nm 
1-60Hz adjustable
nitrogen 337nm 10Hz 
Ion source 
technology 
Delayed extraction technology
Ion source 
pattern 
Positive and negative ion sources
Vacuum system 
capacity  
10-6pa 10-7pa 10-4pa 
Detection 
system  
Micro-channel plate detector Electron multiplier  
Shielding the "gate" function of noise peaks
Mass range  >600KDa >500KDa >500KDa >380KDa 
Sensitivity  <1fmol <10fmol
Resolution  >3500FWHM >2500FWHM >700FWHM >1000FWHM 
Accuracy (inner 
calibration) 
≤50ppm ≤50ppm ≤100ppm
Accuracy (outer 
calibration) 
≤150ppm ≤100ppm ≤2500ppm ≤250ppm 
Other features  Patented 
AnchorChip 
MALDI sample 
target 
Zoom optics 
technology, with 
the laser speckle 
ranging 50um to 
200um adjustable
Coaxial laser technology  
WishperMode 
technology reduces 
lab sound pollution 
Unique remote ion source design of big gap, 
keeping ion source from contamination 
Applications Proteomics, SNP, 
biomarker analysis 
Proteomics, SNP, biomarker analysis, tissue 
imaging, microorganism, organ-small molecules, 
clinical examination in hospitals
Table 2. Serum Peptidomics Research Technical Systems 
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1.2.4 Comparison of serum peptidomics research platform 
The three systems, namely, SELDI system, ClinProt system and ClinTOF system, of the 
serum peptidomics research platform are compared in Table 2. 
1.3 Main application areas of serum peptidomics 
For the moment, the serum peptidomics is clinically used in complex diseases involved in 
polygene and featuring multi-cause heterogeneity, like cancer (including colon and rectal 
cancer, lung cancer, hepatic carcinoma, esophagus cancer, stomach cancer, cervical 
carcinoma and nasopharyngeal carcinoma), nerve degenerative diseases (including 
Alzheimer disease, Parkinson's disease, Huntington’s Disease), autoimmune diseases 
(rheumatoid arthritis, system lupus erythematosus syndromes), cardio-cerebrovascular 
disease and palsy, to discover protein/polypeptide profiling and biomarker profiling as 
well as the single biomarker in the serum of sufferers of these diseases, making 
breakthroughs and providing a new tool for the researches of disease pathogeny, drug 
target, diagnosis and treatment. 
2. Research method of serum peptidomics 
The research of serum peptidomics involves in sample detection and data analysis. Fig.7 is 
the work flow of serum peptidomics. As shown in Fig.7, blood samples from the   
 
Fig. 7. Technical Process for Serum Peptidomics 
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pathological group and the healthy control group are collected and then the serum is 
separated from the blood. The serum is mixed with magnetic beads to extract serum 
polypeptides for detection with the mass spectrometry. The spectra obtained can produce 
characteristic spectrum peaks. The meaningful characteristic spectrum peaks are screened 
out with the statistical method. A prediction model is built with the pattern recognition 
method and validated with test data. After continuous optimization, a disease diagnosis 
model and a group of characteristic spectrum peaks can be obtained. 
Briefly, the research includes magnetic beads, detection instrument, analysis software, 
polypeptide identification and clinical model. 
2.1 Polypeptide extraction 
The separation and purification methods adopted in the serum peptidomics research depend 
on the nature of the extracted substance. The commonly used methods for polypeptide 
extraction and separation include: salting removal method, ultra-filtration process, gel 
filtration, isoelectric point precipitation method, ion-exchange chromatography, affinity 
chromatography, adsorption chromatography, countercurrent distribution and enzymolysis 
method. These methods often work together to separate and purify specific substances. 
2.1.1 High Pressure Liquid Chromatography (HPLC)  
HPLC is a favorable method for peptides separation, because the HPLC can complete the 
separation in a short time under suitable chromatographic conditions, and more 
importantly, HPLC is capable of producing polypeptide of bioactivity at the preparative 
scale. Many scholars therefore have done substantive work in looking for the best conditions 
for separating and preparing polypeptide substances. How to maintain the activity of 
polypeptide, how to select stationary phase material and eluent type, how to make analytic 
determination are all contents of the present study. Common methods include: reversed 
phase high pressure liquid chromatography (RP-HPLC), hydrophobic interaction 
chromatography (HIC), Size-Exclusion chromatography (SEC), Ion-Exchange 
chromatography (IEC), Chromatography of Membrane Protein (CMP), High-Performance 
Displacement Chromatography (HPDC) and Perfusion Chromatography (PC). 
2.1.2 Affinity Chromatography  
Affinity Chromatography (AC) is the method of separating substances based on the specific 
affinity between ligand connecting to the stationary phase matrix and the ligand having 
interaction with the specificity. Since 1968 when Cuatrecasas put forward the concept of 
affinity chromatography, in searching for the specific affinity interaction substances many 
combinations have been found, like antigen-antibody, enzyme-substrate, agglutinin-polyose, 
oligonucleotides and their complementary strands. For the separation of polypeptide 
substances, currently the monoclonal antibody or biological simulation ligand can be used for 
affinity to such substances. These ligands can be natural or artificially synthesized according to 
their structure. Immobilized Metal Affinity Chromatography (IMAC) is an affinity method 
developed in recent years. Some metal ions are chelated on the stationary phase substrate, like 
Cu2+, Ni2+ and Fe3+. The magnetic beads can be chelated through the coordination bond to 
connect polypeptides that contain Lys, Met, Asp, Arg, Tyr, Glu and His on the side chain. In 
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particular, structures with the peptide sequences containing His-X-X-X-His are easiest 
combined to the metal ion affinity column, featuring good purification effect. 
2.1.3 Capillary Electrophoresis  
Capillary electrophoresis (CE) was invented by Hjerten at the 1960s on the basis of the 
conventional electrophoretic technology and improves the electrophoresis efficiency by 
dozens of times by replacing the large electrophoresis tanks with the capillaries. This 
technology developed rapidly from 1980 and became a good tool for separation and 
determining the nature of polypeptides and protein substances by bio-chemical analysts and 
biochemical scholars. By application principles, CE can be divided into: Capillary Zone 
Electrophoresis (CZE), Capillary Isoelectric Focusing (CIEF), Capillary Gel Electrophoresis 
(CGE) and Micellar Electrokinetic Electrophoresis Chromatography(MECC).  
2.1.4 Solid phase protein chip technology 
The solid phase protein chip technology usually refers to the sample separation part of the 
SELDI system. The SELDI can not only use the enzyme, antibody, receptor and DNA as the 
sorting basis of chips, but also take chemical mediators of different natures as the protein 
sorting basis according to the different chemical natures of proteins, thereby to reduce the 
requirement on the sample purification and enlarge the sorting range of samples. SELDI 
chips can be divided into the chemical surface chips and biological surface chips according 
to the detection purpose. The former include hydrophobic surface (H4), normal phase (NP), 
weak cation exchange (WCX), strong anion exchange (SAX) and immobilized metal affinity 
capture (IMAC) and the latter include antibody-antigen surface chips, receptor-ligand 
surface chips, enzyme-substrate surface chips and DNA-protein surface chips, specifically 
for detecting the corresponding polypeptide molecules. 
2.1.5 Liquid phase protein chip technology – Magnetic bead 
The magnetic bead is a new multifunctional reagent developed in recent years and widely 
used in biomedicine. Owing to diversified surfaces of macromolecular coat, magnetic beads 
can be coupled with various biologically active substances (like antibody, antigen, receptor, 
enzyme and nucleic acid), which can be fixed to the magnetic beads to further identify 
corresponding antigen or antibody, ligand, substrate, nucleic acid in the reaction medium, 
thereby to realize separation or detection. The results show magnetic beads have functions 
of both the carrier and separation performer. They can simplify complicated operations by 
utilizing the physical, chemical and biomedicine principles, thereby to greatly shorten the 
period of conventional test. Different from protein chips, magnetic beads are composed of 
many magnetic spherical granules, which provide them with greater surface area and 
enable them to combine more specific proteins and to have higher sensitivity and accuracy. 
To be detailed, the disease associated differential protein liquid chip SPE-C magnetic beads; 
hydrophobic MB-HI C 1 (suitable for purification and enrichment of proteins more-than-
20kDa), MB-HI C 3 (suitable for purification and enrichment of 8-20kDa proteins), MB-HI C 
8 (suitable for purification and enrichment of 1-10 kDa proteins/polypeptide), MB-HI C 18 
(suitable for purification and enrichment of less-than-4kDa polypeptide); metal affinity 
magnetic beads include MB-IMAC-Fe (for capture and enrichment of phosphorylation 
proteins) and MB-IMAC-Cu (for the capture and enrichment of specific affinity 
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proteins/polypeptides); ion exchange magnetic beads include MB-WCX (purification and 
enrichment of acid proteins with the cation-exchange chromatography technology) and MB-
WAX (purification and enrichment of basic proteins with the anion-exchange 
chromatography technology); glycoprotein magnetic beads include ConA and ConB (for 
purification and enrichment of glycoprotein); the immune fishing liquid chips include 
immune affinity magnetic bead ProteinG (the ProteinG on the magnetic bead can combine 
with any one antibody, for screening specific antigens). 
2.1.6 Systematic applications of polypeptide separation engineering 
Polypeptide separation technologies mentioned above are combined to use in practice. 
Different separation tools will be used according to the nature of polypeptide. In particular 
in the post genome era, researches on the proteome are deepened and people are making 
continuous progress in tools for separating polypeptides and proteins. They have 
comprehensively utilized natures of proteins and polypeptides and adopted both the 
routine protein and polypeptide extraction methods aforementioned and also the high 
efficiency liquid chromatography, capillary electrophoresis and 2-d electrophoresis, to get as 
many polypeptides as possible. 
2.2 Sample detection 
2.2.1 Detection of N-terminal sequence with Edman degradation method 
The Edman degradation method used for sequencing can obtain a precise peptide sequence, 
therefore making it a major method for protein identification. Yet its sequencing speed is 
slow and expansive. With technical breakthroughs in microsequencing and speed, Edman 
degradation method will exert a major role in proteome researches. The C-terminal Maxam-
Gilbert method, similar to Edman, has been studied for years and produced automated 
analyzers, but its reaction efficiency is low and usually requires more samples. 
2.2.2 Amino acid composition analysis 
Amino acid composition analysis is frequently used for protein identification owing to its 
low cost. Different from the peptide mass or sequence tags, amino acid composition analysis 
identifies proteins by utilizing the specific amino acid component of different proteins. This 
method can be used for identifying 2-DE separated proteins. The radio-labeled amino acid is 
used to determine amino acid components of proteins, or the proteins are converted to the 
PVDF membrane and after the automatic derivation of amino acid, undergo 
chromatographic separation to obtain data. Then, inquiries are made to the database to rank 
proteins in the database by the amount of difference of two components, as a result, the top 
ranking proteins having greater reliability. Yet this method has some defects: slow speed 
and require a great amount of proteins or peptides; restricted in the ultramicro analysis;the 
possible amino acid variation due to the incomplete acidic hydrolysis or partial degradation. 
2.2.3 Mass Spectrometry 
Mass Spectrometry (MS): MS is an analytical technique that measures the mass-to-charge 
ratio (or mass) of charged particles, molecules or molecular fragments. MS provides 
information of molecular weight, molecular formula, isotopic element composition of 
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molecules and molecular structure of samples analyzed. It has been widely applied in 
protein and polypeptide analysis. In particular, it is suitable for the analysis and 
identification of polypeptide substances in the online analysis after separation and 
purification due to its hypersensitivity and rapidity. Commonly, MS includes electrospray 
MS (in the spray process, the continuous ionization method makes the polypeptide samples 
ionized), fast atom bombardment MS (FAB MS) and isotopic element MS. Among them, the 
Continuous-Flow Fast Atom Bombardment, cf-FAB) and the Electrospray Ionization (ESI) 
have just been developed in recent years. 
Continuous-Flow Fast Atom Bombardment(cf-FAB): a kind of weak ionization technology, 
it is capable of ionizing peptides or small-molecular-weight proteins into the form of MH+ 
or (M-H). It is mostly applied in the separation and detection of peptides and has moderate 
resolution, with the accuracy greater than +0.2amu and flow rate of 0.5-1.5μl·Ml-1. In the 
determination, the mobile phase shall be added with 0.5%-10% substrate like glycerol and 
high organic solvents, so that samples can be sensitized at the detection probe. The cf-FAB is 
usually used together with HPLC and CEZ, to realize the purpose of isolation analysis. The 
cf-FAB analysis methods have been built for many polypeptides and well applied. 
Electrospray Ionization (ESI): able to generate multivalent ionized proteins or polypeptides, 
allowing analyzing of proteins with the molecular weight reaching 100kD; its resolution is 
1500-2000 amu and accuracy about 0.01 %. ESI is more suitable for the online analysis of 
proteins with large molecular weight and requires gasification or organic solvents for the 
sample sensitization. It has been a success to combine ESI and HPLC for separation and 
analysis of GH and hemoglobin. ESI can also be used together with CEZ.  
MALDI-TOF MS: in this method, the ionization of polypeptide samples is realized with the 
substrate absorbing the laser energy. It is a tool for accurately determining the molecular mass 
in the current protein identification and particularly suitable for the determination of the 
molecular weight of mixed proteins and polypeptides, featuring high sensitivity and 
resolution. For the moment, it is a necessary tool for the proteomics research. Working with 
the coupling technique of the liquid chromatography, this method can identify polypeptides at 
a high efficiency. Especially, when MS technologies of different principles are coupled, they 
can not only obtain the molecular weight of polypeptides, but also determine the sequential 
structure. This technology will exert a decisive effect in the future proteomics study.  
2.2.4 Nuclear Magnetic Resonance 
Nuclear Magnetic Resonance (NMR): NMR profiling has purely digital signals, excessive 
overlapping range (due to the large molecular weight) and weak signals, so it is seldom used 
in analysis of proteins and polypeptides. In company with the application of 2D, 3D and 4D 
NMR and the progress of molecular biology and computer processing technology, NMR has 
gradually become a main approach for analysis of proteins and polypeptides. NMR can be 
used for determining amino acid sequence and the content of components in mixtures. Yet 
some problems need solving if this method is used for protein analysis, for instance, how to 
give proteins with large molecular weight a specific shape to facilitate quantitative and 
qualitative analysis and how to reduce the data processing time, which are being studied by 
many scholars. Despite of its infrequent use in the protein analysis, NMR is extremely useful 
in analyzing small peptides with the molecules having less than 30 amino acids, in which case, 
it can overcome the foregoing defects and realize rapid and accurate analysis.  
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2.2.5 Others  
Besides the foregoing methods, amino acid composition analysis, amino acid sequence 
analysis, Field Desorption Mass Spectrometer (FDMS), IR, UV spectra, circular dichroism 
spectrum, bioassay technique, tagging method and immunologic method have also been 
used for the result identification, analysis and detection of polypeptides.  
2.3 Analysis method 
Regarding research on serum peptidomics, the analysis of data collected shall have: high-
efficient analysis technical platform, computer and network have become a necessary tool of 
biological research; high throughput technical platform, mainly targeting at how to use the 
information technology to analyze the giant data; data mining technical platform, which 
shall be able to mine knowledge from the massive data saved in database or other 
information banks for the analysis; data visualization technical platform, in describing the 
systematic relations, the functions of nucleic acid, protein, cell, organ and tissue shall be 
considered, that is to say, a systematic method shall be used to learn about vital activities. 
Currently, databases used for proteomics research include SWISS-PROT, BLOCKS, SMART, 
PROSITE, WORLD-2D-PAGE, EMBL, GenBank, DDBJ, ProClass, PR INTS, MASCOT, 
PROTO-MAP, DOMO, PDB and NCBI. Among them, SWISS-PROT is a real protein 
sequence database and also the largest and most diversified proteome database in the 
world. EMBL is to collect protein sequences that have been translated from nucleic acid 
automatically and not yet entered the SWISS-PROT. NCBI contains protein sequences 
translated from DNA in the GenBank and from the PDB, SWISS-PROT and PIR databases. 
Presently, many tools and methods used for MS data process and analysis of serum 
peptidomics have been developed, mainly including: 
2.3.1 Bioconductor 
Bioconductor is an open source and open development software project, with the broad 
goals of providing widespread access to a broad range of powerful statistical and graphical 
methods for the analysis of genomic data, facilitating the inclusion of biological metadata 
and driving comprehensive analysis and application of data. Its application function is to 
provide users with the integrated packages. It has also provided many packages of MS data 
processing and analysis for users. Bioconductor is based on the R language, so it requires 
that users must be familiar with the R-language working environment and have some 
knowledge of programming, that is to say, it will be difficult for the general clinical and lab 
workers. 
2.3.2 MATLAB 
MATLAB is a piece of commercial software integrating statistical analysis and engineering 
computation. Taking MATLAB as the development platform, it will be possible to realize 
the pretreatment, display and statistical analysis of MS data. In the research of serum 
peptidome profiling of prostatic cancer, breast cancer and bladder cancer, this tool together 
with the GENESPRING of Agilent has achieved good results in data analysis (Villanueva et 
al, 2005). 
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2.3.3 TOF-MS Based Software 
1. Spectrogram Pretreatment 
Due to many influencing factors in the MS experiment, the original spectrogram produced 
by MS must be pretreated to eliminate disturbance. Pretreatment of the MS data includes 
baseline elimination, filtration and noise elimination, standardization, peak detection and 
peak quantification. The comparison of commonly-used pretreatment methods and tools are 
shown in Table 3 (Cruz-Marcelo et al, 2008). 
 
Algorithm and 
Tool  
Main Functions Relevant Information 
ProteinChip 
Software 3.1 and 
Biomarker 
Wizard 
Commercial software of 
Ciphergen Biosystems, 
designed for analyzing 
SELDI-TOF MS data 
http://www.vermillion.com/ 
PROcess An R-language based 
package of BioConductor, 
designed for pretreatment of 
SELDI-TOF MS
http://www.bioconductor.org/pac
kages/bioc/1.8/html/PROces 
s.html 
Cromwell MatLab script to realize MS 
data pretreatment  
http://bioinformatics.mdanderson.
org/cromwell.html 
SpecAlign MS data pretreatment and 
peak alignment
http://physchem.ox.ac.uk/~jwong
/specalign/index.htm
MassSpecWavelet An R-language based 
package of BioConductor, 
using continuous wavelet 
transform for peak detection  
http://www.bioconductor.org/pac
kages/2.0/bioc/html/MassSpecW
avelet.html 
Table 3. Commonly-used MS Pretreatment Algorithms and Tools 
2. Peak Alignment 
The spectrograms after pretreatment shall undergo peak alignment. Many spectrograms are 
combined into a matrix file similar to the gene expression profile, namely the serum 
peptidome profiling. In the profiling, the line represents the peak of some specific charge-
mass ratio (m/z), namely, the relative content of specific proteins or polypeptides, and the 
column represents samples. This is the foundation for follow-up bioinformatics analysis and 
its data quality directly influences the analysis results. 
3. Bioinformatics Analysis 
Usually, the first step is to make cluster analysis, mainly including shortest distance method, 
longest distance method, median method, centroid method, average linkage and Ward's 
minimum-variance method. Also, the data classification is carried out. The commonly-used 
methods include support vector machine (SVM), decision tree, neural networks and k 
nearest neighbor (kNN). 
The research process based on serum peptidomics classification is first to divide the mass 
spectrometric data after pretreatment into a group of modeling data and the other group of 
validation data. The modeling data fall into the training set and testing set. Then, analysis 
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will be performed over the training set with t-test, Pearson correlation analysis and genetic 
algorithm, to find peaks of higher specificity to build a sorter. Then, the testing set makes 
tests, which shall be repeated and optimized. Finally, the validating data are used for 
validating to get a stable model. 
4. TOF-MS System Based Softwares 
Softwares based on the TOF-MS system mainly includes: (1) for the SELDI system, the 
ProteinChip Software 3.1 and Biomarker Wizard taking the decision tree as the core; (2) for 
the ClinProt system, the ClinProTools software taking cluster analysis as the core; (3) for the 
ClinTOF system, the BioExploerTM software taking specific vector machine (SVM), decision, 
tree, neural networks and k nearest neighbor (kNN) as the core. 
Other bioinformatics tools for MS correlation analysis include: MapQuant, MASPECTRAS, 
SpecArray, msInspect and MZMine. These tools or softwares haven't realized seamless 
connection with serum peptidomics data, so they fail to perfectly accomplish the data 
management and analysis based on MS serum peptidome profiling. 
3. Disease serum peptidomics research progress 
Nowadays in clinical detection, the serum biochemical indicators fail to accomplish the task 
of diagnosing complex diseases. For instance, there are only one or two serological diagnosis 
indicators available for specific cancers; even worse, these indicators cannot diagnose 
diseases independently and sometimes confuse the cancer with benign tumors or 
inflammation. For example, the prostate specific antigen (PSA) is a major diagnosis indicator 
for prostatic cancer, but not a biomarker for the prostatic cancer specificity, for the reason 
that 15%~25% prostatic cancer patients see their serum PSA falling into the normal range. 
Besides, PSA may also rise due to the benign hyperplasia of prostate, urinary infection, 
acute prostatitis, retention of urine and the per rectum operations. Accordingly, serum 
peptidomics analysis, as a new clinical diagnosis method, has made great progress in early 
diagnosis of complex diseases like tumor, neurological degenerative diseases and 
autoimmune disease. 
3.1 Tumor 
3.1.1 Ovarian cancer  
Ovarian cancer is the most maligne tumor among all malignant tumors of the reproductive 
system, with the pathogenic factors unclear yet but possibly relating to the reproductive and 
hereditary factors. Most ovarian cancer cases are detected in the late stage and seldom 
cured. For the moment, the universally-ratified specificity biomarker CA125 for ovarian 
cancer diagnosis, as the single biomarker, sees the positive predicted value less than 10%. 
Therefore it is urgent to develop an approach for the early-stage clinical diagnosis so as to 
enhance the survival rate. The serum based peptidomics has seen great progress in 
researches of ovarian cancer diagnosis. 
Pleasantly, based on findings of the SELDI system, the US Vermilion Company and Quest 
Diagnostics worked together to develop the OVA1, which can determine the onset of 
ovarian cancer by detecting the cavum pelvis enclosed mass and decide whether operations 
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are needed, what operations are needed and who shall perform the operations if applicable. 
OVA1 ovarian cancer qualitative serum test forms a single digital grading system by 
combining the five immunoassay combinations. The test has shown that female older than 
18, requiring operations of ovarian enclosed mass and not examined by the oncologist can 
undergo examination with OVA1. This immune test has determined five tried and true 
biomarkers, namely, thyroxin, apolipoprotein A-1, ǃ2-microglobulin, transferin and cancer 
antigen 125. One algorithm is decided to determine the probability of tumor onset of female 
cavum pelvis enclosed mass. Quest Diagnostics exclusively provides OVA1 to the US 
clinical lab for three years. Food and Drug Administration (FDA) has approved OVA1 to be 
used for the high-sensitivity testing of ovarian cancer, with effect better than biopsy or 
operation examination, even if the radiation test results cannot show whether malignant 
tumors exist. Vermilion is devoted to discovering, developing and commercializing new-
style high-value diagnostic tests, to help doctors diagnose, cure and perfect prognoses of the 
patient. Vermilion provides approaches for diagnosis of tumor, blood and heart disease and 
for ensuring women health (OVA1, Fremont, CA: Vermillion, Inc; 2009). 
Petricoin et al., with the fund from the clinical proteome plan of the US FDA/NIH, has 
successfully applied the serum polypeptide profiling technology to make diagnosis of early-
stage ovarian cancer. The ovarian cancer serum proteomics findings with the hydrophobic 
chips were reported: they discover that the content of five types of proteins in the serum of 
ovarian cancer patients and the healthy people is changing at the same time, which is of far 
reaching importance to the diagnosis of ovarian cancer. This proteome worked as the 
specificity biomarker for diagnosing ovarian cancer and double-blind researches were done 
to the serum of the healthy people, ovarian cancer patients and ovarian benign pathological 
changes, with results showing that the sensitivity of this method is 100%, specificity 95% 
and positive predicted value 94%; by contrast, the positive predicted value of CA125 was 
only 35% (Petricoin et al, 2002). 
Katherine et al. utilized the protein fingerprint technology to load 184 serum samples on the 
strong anion exchange (SAX) chips. The 184 cases included 109 ovarian cancer cases, 19 
benign ovarian tumor cases and 56 healthy people. The univariate and multivariate statistics 
method has been applied for analysis. From the protein fragments from the 140 serum 
samples, 3 groups of protein markers of diagnosis significance were obtained: the first 
group included 5 candidate protein markers, with the ovarian cancer sensitivity of 95.7%, 
specificity of 82.6% and accuracy of 89.2%; the other two groups of protein markers included 
5 and 4 candidate protein markers respectively, with the sensitivity of 81.7% and 72.8%, 
specificity 94.9% and of 94.9% and accuracy of 88.2% and 83.9% respectively. After screening 
out 3 groups of protein markers, the rest 44 unknown serum samples were used for blind 
validation, showing that when the three groups were employed together, 41 serum cases 
were diagnosed correctly, to be detailed, 21 ovarian cancers were correctly diagnosed, 11 
ovarian cancers of the progressive stage were correctly diagnosed and 10 of the 11 ovarian 
cancers of the early stage were confirmed; 6 low-malignancy potential tumors were 
diagnosed, 5 of the 6 benign tumors were excluded the possibility of ovarian cancer, 1 of the 
10 serum cases of healthy people had a wrong diagnosis. In this sense, Katherine et al. 
believed that they had found ovarian cancer protein marker groups of diagnosis significance 
and can effectively distinguish healthy people from the benign/malignant ovarian tumors. 
Ye et al. utilized the protein chip technology to analyze the serum of 80 ovarian cancer 
patients and 91 healthy people, discovering the differential protein peak at the position with 
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the molecular mass of 11700 Da, which was obviously higher than the density peak value of 
the control group. Then, the affinity chromatography method was used for purification of it 
and the protein sequence was then determined with the fluid chromatography and mass 
spectrometer. A polypeptide chain was synthesized. Finally, it was identified that this 
polypeptide fragment was haptoglobin chain and corresponding antibody was derived. 
Combined with CA125, this method saw the ovarian tumor diagnosis sensitivity of 95.7%, 
specificity 82.6%, enhanced the early diagnosis rate of ovarian cancers and lowered false 
positive of CA125. Currently, relevant technologies started being applied in screening 
ovarian cancers. 
In addition, theses published on Lancet indicated the MS technology was used to analyze 
the composition pattern of serum peptidome and based on the pattern, found out 
differential points for detection of ovarian cancer clinically. Results showed that 50 ovarian 
cancer patients were all detected, with 18 patients suffering stage-I ovarian cancer; 63 of 66 
gynecologic benign tumors were diagnosed correctly. In detection of ovarian cancer, the 
sensitivity, specificity and positive predicted value of this method were 100%, 95% and 94% 
respectively, much better than the conventional CA125 detection. In particular, it was 
successful in diagnosing the early-stage ovarian cancer (stage I), indicating that this 
technology may be used for the early-stage or early warning detection of ovarian cancer 
hopefully. Thereafter, a series of theses on the serum peptide profiling technology for 
disease diagnosis were published in the world. For instance, in 2004, Soltys et al. with the 
Stanford University published results of using serum peptidome profiling to diagnose 
squamous carcinoma on Clinical Cancer Research; in 2005, Kaz’ufumiHonda et al. with the 
Japanese National Cancer Center published thesis on utilizing low-resolution MS and high-
resolution MS to diagnose pancreatic cancer on Cancer Research. At the beginning of 2006, 
Villanueva et al. with the US Sloan-Kettering Cancer Center published an article on using 
serum peptide profiling technology to diagnose bladder cancer, breast cancer and prostatic 
cancer; at the end of 2006, Nature published remarks on this article, signaling its support for 
this technical development and application. Lately, Lancet published an article on using the 
serum peptide profiling technology to diagnose tuberculosis, which produced sensitivity 
and specificity greater than 950k. 
3.1.2 Breast cancer 
We employed the ClinTOF system in the research of breast cancer, with the experimental 
design as shown in Fig.8. The serum polypeptides were extracted with magnetic beads and 
then the polypeptide profiling was obtained with MS detection, to build a disease model. 
Significant difference was found with the software analysis and the reliability of the model 
was validated with a certain number of blind samples. At the same time, the reliability of 
the difference was confirmed. Multiple tandem mass spectrometry were used to identify 
differential polypeptides. FlexAnalysss2.4, BioExplorer, SIMCAP+ and ClinProTools2.0 
were used to analyze results, as shown in Fig.9, finding out 4 differential peaks; 
identification and functional forecast were performed on differential polypeptides. 
Most of the polypeptide sequences identified lacked of only one or several amino acids. 
After comparing them with results and discussions in literatures, it was concluded that 
under different disease response conditions, the activity of external peptidase would 
undergo changes, thereby to obtain a series of polypeptides by cutting different protein loca. 
These polypeptides might share the same modif. 
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Fig. 8. Experimental Design of ClinTOF System for Breast Cancer Research 
 
A: sample distribution diagram; B: average profiling of significantly differential peaks; C: distribution of 
samples obtained by SIMCAP+; D: results of MS identificdatin of differential polypeptides;  
E: description of mechanism according to distribution of identified polypeptides 
Fig. 9. Findings of Using the ClinTOF System to Breast Cancer Research 
Breast Cancer group
Control group 
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Some researchers have also shown that protein MS peaks obtained by the SELDI system can 
effectively screen and distinguish the breast cancer and non-breast cancer patients. Van 
Winden et al. adopted the SELDI technology to determine the density difference between 
the breast cancer group and the control group, making new progress compared with the 
previous breast cancer marker protein reseraches (van Winden et al, 2009). Gast et al. 
utilized the SELDI technology to detect the protein profiling in tissues and serum to 
diagnose breast cancer, showing that 3 peaks are significantly correlated to breast cancer. 27 
tissues were detected to have differential peaks. These protein fragments presented 
potential pathological and physiological mechanisms related to breast cancer, which is 
helpful for raising the diagnosis rate of the breast cancer (Gast et al., 2009). Taku et al 
employed the SELDIS technology to detect 65 breast cancer patients as a group, concluding 
that the overexpression of a non-identified protein and the underexpression of the other are 
related to the lymphatic metastasis of breast cancer (Taku et al., 2006). 
3.1.3 Nasopharyngeal carcinoma 
In the early stage, if nasopharyngeal carcinoma fails to show some disease features due to 
disturbance of some factors, the test method is so insensitive that the patient cannot get 
timely and correct diagnosis, it will delay the treatment and cause unfavorable prognosis. In 
the research on nasopharyngeal carcinoma serum peptidome, some progress has been 
made. 
We employed the ClinTOF system to research the marker of early-stage nasopharyngeal 
carcinoma. The magnetic bead system was SPE-C. By comparing 40 nasopharyngeal 
carcinoma cases and 61 healthy people, 65 significantly differential peaks were observed in 
the mass range of 1,000Da-10,000Da. The peak with the most obvious difference of 
expression has the mass-to-charge ratio of 1262.67 and is identified with the LTQ -Orbitrap 
to be the fragment of fibrinopeptide A. Fibrinogen is a kind of glycoprotein rich in blood 
and a symmetrical dimer composed of 6 polypeptide chains; it plays a major role in blood 
coagulation and hemostasis. So far, more than 300 fibrinogen natural mutants have been 
discovered, among which, about 55% are subclinical, 25% have hemorrhagic tendency and 
20% have thrombophilia. Among these mutants, the most common expression is that one 
amino acid is replaced by another. At the molecular biology level, expressions are point 
mutation, deletion, insertion and nonsense mutation. Moreover, the polymorphism of the 
fibrinogen results in the overexpression, which raises the fibrinogen level of plasma and 
closely relates to diseases. 
Researchers have also indicated that this system has a higher repeatability than the IMAC 
Cu2+ chips (Ciphergen Company) and is capable of finding more differential peaks in 
proteins with the molecular weight ranging 2,000Da -5,000Da. 
Wei et al., using the SELDI system, screened out the mass-to-charge ratios of four proteins, to 
be detailed, 4 097Da, 4 180 Da, 5 912Da and 8 295Da, which make a marker combination to 
build a classification tree model for diagnosis of nasopharyngeal carcinoma. In diagnosing 
nasopharyngeal carcinoma, the sensitivity and specificity of this model were 94.5 % and 96.7% 
respectively and for the blind screening group, the two figures were 92% and 92.9% 
respectively. Using the protein MS peaks with the mass-to-charge ratio of 4 581Da and 7802Da 
to predict the stage I and stage II nasopharyngeal carcinoma, the accuracy proved to be 80% 
and for the stage III and stage IV, this figure was 86% (Wei et al, 2008). 
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Guo et al. applied the SELDI system and the artificial neural network technology to analyze 
serum of 58 type-A (cranial nerve type: featured by basicranial destruction and cranial nerve 
violation, no lymphonodi cervicales metastasis) and type-D (lymphonodi cervicales 
metastasis type: widespread metastasis of one- or two-sided lymphonodi cervicales, no 
cranial nerve violation or basicranial bone destruction) nasopharyngeal carcinoma patients 
and obtained 11 potential biomarkers, with the mass-to-charge ratio of 4 053, 5 885, 4 072, 5 
798, 4 209, 8 689, 2 382, 9 357, 2 221, 4 230Da and 5 901Da respectively. The MS peaks of these 
proteins saw accuracy for distinguishing type A and type D reach 90% (Guo et al, 2005). 
Cho et al. employed IMAC3-Cu protein chips to detect the serum of the healthy people, 
modified nasopharyngeal carcinoma patients after treatment and the relapse 
nasopharyngeal carcinoma patients before and after chemotherapy, discovering 13 
meaningful protein MS peaks. Protein MS peaks with the mass-to-charge ratio of 2950Da 
and 6 701Da were selected to build a classification tree model for predicting chemotherapy 
response, with the sensitivity and specificity of 80% and 87% respectively. In detection and 
analysis of serum protein profiling of the healthy people and the relapse nasopharyngeal 
carcinoma patients, it is newly discovered that the MS peaks with the mass-to-charge ratio 
of 3803Da and 3953Da were found in the serum of both patients taking the initial diagnosis 
and treatment, and the modified nasopharyngeal carcinoma patients after treatment. In 
addition, the protein MS peaks with the mass-to-charge ratio of 3953Da and 7765Da were 
identified to be the inter-alpha trypsin inhibitor heavy chain H4 precursor (ITIH4) 
fragments and platelet factor 4 (PF4) with the method of MS/MS sequence and immune 
affinity capture test, thus presuming that they are related to the onset, development, 
metastasis and relapse of nasopharyngeal carcinoma (Cho et al., 2004). 
Huang et al. adopted the CM 10 chip and SELDI technology to detect squamous epithelial 
cells of the nasopharyngeal carcinoma patients and made contrast with serum of the healthy 
people. 94 protein MS peaks were detected, among which, 26 were obviously different from 
the serum of healthy people (P<0.05, Mean>SD), 5 of overexpression and 21 
underexpression. Three protein MS peaks with the mass-to-charge ratio of 3159 83, 5 187 65 
and 1 3738.6Da were selected to build a diagnosis model. Verified by the blind method, this 
diagnosis model has accuracy of 90.63%, sensitivity 95.00%, specificity 83.33%, positive 
predicted value 90.48% and negative predicted value 90.90%, indicating that this model has 
a higher diagnosis value for NPC (Huang et al, 2008). 
Doustjalali adopted the ClinProt system and the MASCOT database retrieval, discovering 
that in the serum of nasopharyngeal carcinoma patients, the content of CPL showed 
overexpression compared with the control group; further, after the ELISA method 
validation, it was discovered that in the nasopharyngeal carcinoma tissues, CPL showed 
overexpression. After 6 months' treatment, the CPL content in tissues reduced. CPL is a kind 
of copper-bearing glycoprotein and considered to be a key molecule for activating 
angiogenesis factor, which can promote growth of tumors, as shown by studies. This 
research monitored the changes of ceruloplasmin in company with the ease of the disease 
with the proteome technology, which would play a role in diagnosis, curative effect 
observation and prognoses evaluation, observation and monitoring of nasopharyngeal 
carcinoma (Doustjalali et al., 2006). 
Liao et al. adopted 2-DE /MALDI-TOF-MS technology to screen tumor specific antigens of 
nasopharyngeal carcinoma. High-abundance protein elimination and desalting pretreatment 
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were performed over serum of the nasopharyngeal carcinoma metastasis group, 
nasopharyngeal carcinoma non-metastasis group and the control group. Then, analysis was 
made to the 3 groups of serum profiling, obtained 29 differential protein spots and 
identified 23 proteins. Through comparison of the cancer profiling and the profiling of the 
control group, it is discovered that the transferrin, zinc finger protein 544, thyroid hormone 
binding protein, NM 23H 1 protein and FAD synthetase showed underexpression in 
nasopharyngeal carcinoma patients. Yet lipoxygenase (LOX), serum amyloid protein A1, 
cytochrome P450, sICAM1, cathepsin G and histone lysine specific demethylase 1 showed 
overexpression in the two groups of nasopharyngeal carcinoma patients; the LOX, sICAM1, 
cathepsin G and histone lysine specific demethylase 1 showed higher expression in the 
nasopharyngeal carcinoma metastasis group than in the non-metastasis group, while the 
heat shock protein 70 was only expressed in the nasopharyngeal carcinoma metastasis 
group. In addition, by combining the immune histochemical technique and ELISA method, 
it is concluded that HSP70, sICAM1 and serum amyloid protein A (SAA) were potential 
serological markers for mediating nasopharyngeal carcinoma metastasis and also exerted an 
important role in clinical detection and control of nasopharyngeal carcinoma (Liao et al, 
2008). 
3.1.4 Cervical carcinoma 
The serum peptidomics technology has been used in the research of endometrial carcinoma 
and is of guidance significance for the early diagnosis and clinical grading of diseases. 
Our researches using the ClinTOF system have indicated that in the cervical carcinoma 
group and the control group, the protein peak intensify difference of only 21 proteins had 
statistical significance (P<0.05). M1450.35Da, M1778.7Da, M1896.65Da and M5520.42Da 
were taken as the classified variables to build a classification predictive model, to make 
classification diagnosis over the cervical carcinoma group and the control group, with the 
identification rate and predictive ability of 90.45% and 81.75% respectively. By contrasting 
the proteome of different pathological differentiation degrees, it is discovered that the 
protein peak intensity difference of 2 proteins had statistical significance (P<0.05). 
M5904.14Da and M5264.26Da were taken as the classified variables to build a classification 
model, to make classification diagnosis on different differentiation degrees, with the 
identification rate and predictive ability of 81.48% and 78.89% respectively. 
Yoshizaki et al. adopted the SELDI system to analyze the protein profiling of 19 endometrial 
carcinoma cases and 20 normal tunica intima tissues, discovering two differential proteins, 
namely EC1 and EC2. The former had overexpression in the endometrial carcinoma tissues 
and the latter on the contrary. These differential proteins may be used for diagnosing 
endometrial carcinoma hopefully (Yoshizaki et al., 2005). 
3.1.5 Leukemia 
The treatment of acute leukemia (AL) depends on minimal residual disease (MRD) 
diagnosis and detection. However there has been no serum biomarker that can be used by 
the clinicians for diagnosing AL and evaluating MRD. Yang et al. analyzed serum of AL 
patients, discovering two peptides (m/z of 1778 and 1865) reduced with the rise in the 
modification degree and that 1865 was related to AL types. After further FT-ICR-MS 
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detection, the two peptides are the C3F fragment. The linear regression analysis has 
indicated that the combined use of the peptides could distinguish PML / RARǂ positive 
molecules from M3. Findings show that the two C3F fragments are significantly correlated 
with the MRD level and can be used for evaluating clinical MRD (Liang et al., 2010). 
3.1.6 Brain glioma 
Our forward-looking researches on brain spongiocytoma diagnosis have indicated: using 
the SPE-C magnetic bead separation and liquid automatic processing robot operations of the 
ClinTOF system, after MS, 74 differential peaks occurred in the serum of 84 patients and 72 
healthy people. 55 samples were taken randomly to build the MS model of patients and 
healthy people, with the diagnosis specificity for the healthy people reaching as high as 
96.4% (Fig.10). 
 
Fig. 10. Differential Polypeptide Peaks of Brain Glioma 
3.2 Nerve and mental diseases 
Alzheimer disease (AD) is a degenerative disease with unclear causes and mainly 
disturbing cerebral cortex neurons. Zhang et al. discovered that in the serum of AD 
patients, the haptoglobin and complement factor H were overexpressed. Haptoglobin is 
a kind of acute phase reactive protein and an antioxidant, featuring multiple biological 
activities and is considered to have participated in the inflammation process together 
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with lymphocyte, neutrophilic granulocyte and monocyte and played a vital role in 
regulating host defense. Complement factor H is an important complement modulation 
substance and can also work as a significant effector molecule of congenital immunity. It is 
capable of distinguishing self and non-self and the activated and non-activated cell surfaces. 
In the research, the overexpression of two proteins indicates the inflammatory reaction, 
oxidation stress and immunologic mechanism are participating in the onset process of AD 
(Zhang et al., 2004). Hye et al. made case-control study to the plasma of 50 AD patients and 
the control group, discovering many disease pathology related proteins, including 
complement factor H (CFH) precursor and ǂ22 macroglobulin and pointing out that the 
expression of CFH is related to the cognitive dysfunction of AD patients. ǂ22 macroglobulin 
(A2M) is a pan-protease inhibitor. In case of brain damages, the immunological activity of 
A2M of the neuron and colloid cells will rise, especially at the levels of senile plaques, nerve 
fiber matting and auantic neuron neurite (Hye et al., 2006). 
We utilized the SPE-C magnetic beads and ClinTOF system to compare 85 two-way patients 
having no medicine and 100 healthy people, discovering 5 significantly differential peaks in 
the mass range of 800Da-12,000Da among the mental disease patients and the healthy 
people. The serum polypeptide MS standard model profiling has a predictive sensitivity of 
100% for the healthy people and for the mental disease patients, 87%. 
3.3 Healthy people screening 
To study relevancy between some disease and polypeptide, we introduced serum 
polypeptide profiling into health screening. The ClinTOF system was used to study 1980 
healthy people related polypeptide profiling researches, covering the age of 18-75, large 
sample statistics of both sexes, with the experimental design work shown in Fig.11. With  
 
Fig. 11. Experimental Design of Healthy People Screening with the ClinTOF System 
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the SPE-C magnetic bead, MS profiling (Fig.12) for age 5 ranges was built and 10 peaks with 
the most significantly mass-to-charge ratio were identified. The online search of database 
with Mascot indicated that most polypeptide protein precursors were isogenous with the 
human prokinin precursors. After the analysis of serum peptidome profiling and 
bioinformatics data mining of 1890 healthy people, for the healthy people, the profiling has 
no obvious difference regardless of age and sex, but for people younger than 30, the sex 
difference factor shall be considered, that is, the elder the person is, the more different the 
serum peptidome profiling will be. Therefore, in researching the disease peptidome 
profiling, the age and sex matching factors shall be considered. It has also discovered that 50 
polypeptides have a higher frequency of occurrence (more than 30%) in the serum of 
healthy people, indicating that these polypeptides can work as reference for health controls. 
 
 
 
 
A: average profiling of 1890 healthy people; B and C: results from PCA analysis by age and sex; D: some 
peaks of highly-frequent occurrence detected by MS after the treatment by SPE-C magnetic beads 
 
Fig. 12. Results of Healthy People Screening with the ClinTOF System 
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3.4 Fetal congenital aplasia 
We have used the ClinTOF system to study fetal congenital aplasia, with the research 
protocol shown in Fig.13. This thinking has generalized the sample collection strategies and 
the result expectations sufficiently indicating the diversification and universality of serum 
peptide method, and can be used for most research areas. Secretion leukoprotease inhibitory 
factor (SLPI) is an endogenic immunity related protein, capable of specifically inhibiting 
elastolytic enzyme, cathepsin G, trypsin and fibrinolysin and boasts of antiphlogistic 
response and antibiosis/antiviral activity. The detection of the content of SLPI protein in 
serum may have great clinical significance for diagnosis. Differential polypeptides were 
obtained (Fig.14) and their functions were explained (Table 4). 
 
 
 
 
 
 
 
 
 
Fig. 13. Research Protocol for Fetal Congenital Aplasia with ClinTOF System 
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A and B: gel image of differential polypeptides 
Fig. 14. Findings of Rsearching Fetal Congenital Aplasia with the ClinTOF System 
 
 
Table 4. Retrieval Results from Swiss-Prot Protein Database 
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Besides diseases studied by the ClinTOF system above, for the moment, we have finished 
the detection of near 10000 samples. Diseases are not only restricted to tumors, but covering 
almost all clinical aspects, as shown in Table 5. 
 
Disease  Case Load Source  
Lung cancer, lung 
squamous carcinoma, 
adenocarcinoma of lung 
1678 PLA 301 Hospital, Guangzhou People's Hospital, 
Xian Jiaotong University, Hebei Medical 
University Fourth Hospital  
Stomach cancer  117 Fudan University, Shanghai Ruijin Hospital 
Esophagus cancer  48 West China University of Medical Science, 
CICAMS 
Nasopharyngeal 
carcinoma  
238 Sun Yat-Sen University Cancer Center 
Breast cancer  156 Beijing Cancer Hospital, Xinjiang Medical 
University  
Pancreatic cancer  120 Guangzhou People's Hospital 
Endometrial carcinoma 
Endometrial carcinoma  
283 Beijing Obstetrics and Gynecology Hospital, 
Capital Medical University  
Leukemia  103 Shanghai Fifth Hospital  
Intestinal cancer  185 Shanghai Jiaotong University, Capital Medical 
University  
Rheumatosis,  
lupus erythematosus 
75 Shenzhen People's Hospital  
Cirrhosis, hepatic 
carcinoma, hepatitis B  
303 PLA 301 Hospital, Tianjin Third Hospital  
Cognitive dysfunction  230 Zhongnan Hospital of Wuhan University, 
Shanghai Jiaotong University  
Endometriosis uterine  137 Beijing People's Hospital 
Diabetes  188 Shanghai Changzheng Hospital  
Test-tube baby tracking  102 Beijing University Third Hospital  
Mental disease  1220 Chongqing Medical University  
Healthy people  2473 Capital Medical University  
Athletes 1995 PLA 301 Hospital  
Table 5. Diseases and Case Load Applied by the ClinTOF System (alterable) 
4. Prospect 
Clinically, the high incidence and mortality rate of complex diseases like tumors cry for the 
new early-diagnosis patterns and effective early-diagnosis markers. In the mining of the 
mass spectrometric data, the cluster analysis and classification analysis have been used, but 
many problems still need further studies. In particular, the pretreatment of MS profiling, 
there is no standard method available. These issues are critical for putting serum peptidome 
into clinical detection. Secondly, along with the instant development and application of 
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mass spectrometer and serum peptidome technology, a lot of serum polypeptide profiling 
data have been produced. It has become an international competition focus in the post-
genome era how to develop an effective bioinformatics instrument to determine proteins 
related to some vital phenomena (like growth, upgrowth, tumor onset) from the substantive 
data including peptide mass and intensity and their functions. It is believed that with the 
progressive development and application of serum peptidomics technology and the 
ClinTOF system, better clinical models will appear and more early-stage tumor biomarkers 
will be discovered and identified. Also, great breakthroughs will be made in the pathogeny, 
diagnosis and treatment of complex diseases, to cultivate new hope for research, diagnosis 
and treatment of many diseases. 
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